|
Biological Activity:
Somatostatin receptor agonist and also a 5-HT agonist; FK960 stimulates both serotonin and somatostatin production as a cognitive enhancer. However, its development for Alzheimer's disease (AD) was terminated in 2003.
References:
A Graul et al. FK-960, Congnition Enhancer. Drug. Fut. 1997, 22(8), 830-832.
N Matsuoka and TG Ainer. FK960 [N-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide Monohydrate], a Novel Potential Antidementia Drug, Improves Visual Recognition Memory in Rhesus Monkeys: Comparison with Physostigmine. J. Pharmacol. Exp. Ther. 1997, 280(3), 1201-1209. [online]
JP Hodgkiss and JS Kelly. Effect of FK960, a Putative Cognitive Enhancer, on Synaptic Transmission in CA1 Neurons of Rat Hippocampus. J. Pharmacol. Exp. Ther. 2001, 297(2), 620-628. [online]
F Wang et al. Modulation of Ca2+Channel Currents by a Novel Antidementia Drug N-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide Monohydrate (FK960) in Rat Hippocampal Neurons. J. Pharmacol. Exp. Ther. 2004, 308 (1), 120-126. [online]
Chemical name: N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate
|